US FDA extends review of Merus' gene-targeting cancer therapy

Merus NV

05/11/2024 11:35

Nov 5 (Reuters) - The U.S. Food and Drug Administration
on Tuesday extended the review of Merus NV's  MRUS.O 
gene-targeting cancer therapy to allow sufficient time to review
information submitted by the company. 
    The agency will now make a decision on the treatment by Feb.
4 2025, compared to a previous action date of November 6. 
    


 (Reporting by Bhanvi Satija and Christy Santhosh in Bengaluru;
Editing by Abinaya Vijayaraghavan)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))